货号:A403832 同义名: 维格列汀 / LAF237;NVP-LAF 237
Vildagliptin is an inhibitor of DPP-4 with IC50 of 2.3 nM that is used in the treatment of type 2 diabetes mellitus.
规格 | 价格 | 会员价 | 库存 | 数量 | |||
---|---|---|---|---|---|---|---|
{[ item.pr_size ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_am, item.pr_size) ]} | {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]} | 现货 | 咨询 | - + |
快速发货 顺丰冷链运输,1-2 天到达
品质保证
技术支持
免费溶解
描述 | Vildagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor. It improves glycaemic control by inhibiting DPP-4 from inactivating the incretin hormones glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide, prolonging incretin activity in response to ingestion of nutrients. Vildagliptin also showed efficacy in reducing HbA(1c) levels in patients with type 2 diabetes when used in combination with metformin, pioglitazone or insulin. Vildagliptin was generally well tolerated when administered alone or in combination with additional antidiabetic treatment[3]. Oral vildagliptin is a useful option as monotherapy or as add-on therapy for patients with type 2 diabetes[4]. Inhibiting DPP-4 (dipeptidyl peptidase) signaling by vildagliptin could ameliorate pulmonary fibrosis by downregulating EndMT in systemic LPS-induced lung injury[5]. Vildagliptin (35 mg/kg; once daily by oral gavage) increases plasma active GLP-1 levels in islets of db/db mice[6]. Vildagliptin displayed protective capabilities against TNF-α-induced chondrocyte cell cycle arrest in the G1 phase. Moreover, vildagliptin suppresses the three major TNF-α-induced chondrocyte senescence proteins including p53, p21, and plasminogen activator inhibitor-1 (PAI-1). Vildagliptin also suppresses TNF-α-induced p53 acetylation at K382[7]. |
细胞系 | 浓度 | 检测类型 | 检测时间 | 活动说明 | 数据源 |
Caco-2 cells | Function assay | Inhibition of human DPP4 expressed in Caco-2 cells, Ki=0.004 μM | 17034148 | ||
insect cells | Function assay | Inhibition of human recombinant His-tagged DPP4 expressed in insect cells, IC50=0.056 μM | 20718420 |
NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
NCT01582308 | Type 2 Diabetes Mellitus | Phase 1 | Completed | - | - |
NCT01582308 | - | Completed | - | - | |
NCT00099931 | Diabetes Mellitus, Type 2 | Phase 3 | Completed | - | Germany ... 展开 >> Novartis Investigative Site Investigative Sites, Germany 收起 << |
计算器 | ||||
存储液制备 | 1mg | 5mg | 10mg | |
1 mM 5 mM 10 mM |
3.30mL 0.66mL 0.33mL |
16.48mL 3.30mL 1.65mL |
32.96mL 6.59mL 3.30mL |
CAS号 | 274901-16-5 |
分子式 | C17H25N3O2 |
分子量 | 303.399 |
别名 | 维格列汀 ;LAF237;NVP-LAF 237;Zomelis;DSP 7238 |
运输 | 蓝冰 |
存储条件 |
液体 -20°C:3-6个月-80°C:12个月 粉末 Keep in dark place,Inert atmosphere,Store in freezer, under -20°C |
溶解度 |
H2O: 50 mg/mL(164.8 mM),配合低频超声助溶 |
动物实验配方 |